Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

Keytruda Qlex (pembrolizumab and berahydaluronidas alfa-pmph) is a prescription drug approved to treat different types of cancer, such as non-small cell lung cancer and head and neck cancer. Keytruda ...

There were 11 hypersensitivity reactions, all in patients receiving nivolumab. Reducing the infusion time for nivolumab and pembrolizumab to 10 minutes is feasible and safe, according to researchers.

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

Adding belzutifan to pembrolizumab after kidney cancer surgery cuts recurrence risk by 28%, helping high-risk patients stay ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when ...

The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...

Treatment with pembrolizumab plus enfortumab vedotin-ejfv resulted in a statistically significant improvement in EFS compared with radical cystectomy surgery alone. Topline results were announced from ...

A clinical trial shows that combining laser heat therapy with immunotherapy significantly extends the lives of patients with aggressive, recurrent brain cancer.